SCRA

  • Sam Patrick posted an article
    South Carolina firm's NP Collection Swab offers a highly scalable injection-molded design see more

    South Carolina-based Hoowaki LLC has developed an innovative one-piece injection molded design for a COVID-19 swab to help close the gap in U.S. and global COVID-19 testing supplies. The 12-year old micro surface engineering and product solutions company has adapted its proprietary HOOWAKI MICROGRIP® surface technology to create micro-pillars used in the Hoowaki® NP Collection Swab that is shown in clinical user testing to meet existing industry-standard products for flexibility and performance. In independent laboratory testing (qPCR Assay) it has also been proven to be equivalent to the industry-standard flocked filament swabs in the collection of patient RNA that is critical for COVID-19 testing. Mass-production of its FDA registered, patent pending, Hoowaki® NP Collection Swab will begin this summer and is expected to reach at least several million units per month.

    "The Hoowaki® NP Collection Swab is an important answer to the challenges posed by the global COVID-19 pandemic," said Ralph Hulseman, president of Hoowaki LLC. "Our design allows for production to be quickly scaled in communities around the world—rapidly addressing the rising demand for swabs, a critically important element of all COVID-19 testing."

    A recent study by Harvard University [https://ethics.harvard.edu/files/center-for-ethics/files/roadmaptopandemicresilience_updated_4.20.20_0.pdf] cites the need for up to 20 million COVID-19 tests per day by the end of summer. The proprietary Hoowaki® NP Collection Swab is manufactured using advanced injection molding technologies that utilize existing equipment that is readily available in communities throughout the world. The swab's scalability is due to Hoowaki LLC's formulations and engineering designs working at existing injection molding facilities, which enables the swab to be produced in quantities that meet local demands anywhere in the world.

    "Prisma Health collaborated with Hoowaki LLC in the testing and development of the innovative new design. The soft feel and ease of use of the Hoowaki® NP Collection Swab tip impressed my team," said Jennifer Meredith, Ph.D., clinical microbiology director at Prisma Health-Upstate.

    "Prisma Health is excited to see a locally produced solution that could help ease the shortage of swabs for COVID-19 sample collection," said Meredith. "Hoowaki LLC's product has the potential to help us meet our commitment to our patients in the fight against COVID-19." Prisma Health, the largest healthcare system in South Carolina, harnessed its Rapid Innovation Task Force to help with the project.

    Hulseman credits several public-private partnerships that have helped to provide start-up funding for the swab's development: "As is the case for many businesses in today's environment, Hoowaki LLC adapted quickly to meet new challenges where demand is outpacing supply so we could remain not only viable as a company, but also pursue this pioneering technology. We're grateful for the backing of the Greenville Local Development Corporation (GLDC) and SC Launch, Inc., an investment affiliate of the South Carolina Research Authority (SCRA), who have been instrumental in helping us develop the Hoowaki® NP Collection Swab."

    "Hoowaki LLC is a great example of a small business that has proven to be a powerhouse of innovation during a time of incredible challenge," said David Barnett, Chairman of the Greenville Local Development Corporation. "We are proud of our continued support for Hoowaki LLC in the development of the NP Collection Swab."

    To learn more about the Hoowaki® NP Collection Swab visit www.hoowaki.com/covid19-swabs or call Hoowaki LLC at (864) 238-5631. Product inquiries may be sent to alex@hoowaki.com.

    About Hoowaki

    Hoowaki, LLC is a micro surface engineering services and product solutions company that has developed unique micro surface pattern designs, engineering algorithms, software and manufacturing know-how to address major markets. The company's micro surface technology provides grip or slip solutions in the form of films for medical devices, packaging and other industrial and consumer products. Their team includes experienced micro surface engineers, physicists, friction experts, medical device experts, entrepreneurs, inventors and developers. Hoowaki has market deployment partnerships with Havi (packaging) and BvW Holding AG (implanted medical devices). Hoowaki has a broad patent coverage of micro surface technology.

  • Sam Patrick posted an article
    Zylo, Hoth expand relationship see more

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in [SC Launch, Inc., Portfolio Company] Zylö Therapeutics, Inc. (“Zylö”).

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. This small equity investment in Zylö is a further commitment to our belief in Zylö’s science and team.”

    Stated Scott Pancoast, CEO of Zylö Therapeutics, “Partnering with Hoth in 2019 was an important step in propelling our lupus program forward. This equity investment in Zylö stock represents an expansion of the partnership and is a win-win for the two companies.”

    According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.

    ###

    About Zylö Therapeutics, Inc.
    Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of AEA-loaded Z-pods™, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth’s current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption “Risk Factors” in Hoth’s Form 10K for the period ending December 31, 2018, and Hoth’s other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

  • Sam Patrick posted an article
    SCRA added three advisory groups for biomedical sciences, cybersecurity and industry see more

    Summerville, S.C.—South Carolina Research Authority (SCRA) announces the formation of three Business and Science Advisory Boards (BSABs). The purpose of the BSABs is to advise SCRA’s Board of Trustees when requested by it. The boards include representatives from South Carolina research universities, the venture capital/angel investment community, South Carolina Department of Commerce, and industry leaders in the following areas:

    1. Biomedical Sciences
    2. Cybersecurity
    3. Industry 4.0

    Each board provides key business and technical expertise, acts as an independent/ unbiased sounding board for input on SCRA’s program implementation and performance and provides guidance to SCRA regarding funding opportunities. One upcoming funding opportunity on which the BSABs will advise is the SCRA-Academia Collaboration Team (SACT) Collaborative Research Grants. These grants will be available for multi-institutional, collaborative research teams that seek to advance commercially relevant research and address key industry challenges to foster technology-enabled growth of the state’s innovation economy. The solicitation will be released in June.

    “SCRA serves as a bridge between industry and academia. It is imperative that the applied research SCRA funds benefits not only its academic stakeholders, but also South Carolina’s industrial base. The development of the BSABs ensures that the new SACT program achieves those objectives for both stakeholder groups,” said Christine Dixon Thiesing, SCRA Director of Academic Innovations.

    The SCRA fuels South Carolina’s innovation economy by accelerating technology-enabled growth in academia, entrepreneurship and industry. SCRA works with public and private sectors, including industry, to identify market trends and validate the commercial relevance of academic research that SCRA funds. SCRA’s programs and operations had an almost $700 million impact on the state’s economy during the last fiscal year.

     

    ###

    About SCRA

    http://www.scra.org

    Chartered in 1983 by the State of South Carolina as a public, nonprofit corporation, SCRA fuels South Carolina’s Innovation Economy by accelerating technology-enabled growth in research, academia, entrepreneurship and industry.

     

  • Sam Patrick posted an article
    Precision Genetics receives SCRA grant see more

    SCRA announces a $250,000 SC Launch, Inc. investment in Precision Genetics. The life sciences company, located in Greenville, was recently accepted into SCRA’s entrepreneurial program, SC Launch.

    Precision Genetics validated the Emergency Use Authorization (EUA) via the Food and Drug Administration (FDA) to process COVID-19 test kits. Precision Genetics is now available to support state and local healthcare systems in need of public health surveillance, and has priority access to test reagents from commercial reagent manufacturers, which have received EUA from the FDA.

    Precision Genetics provides the test kits for healthcare facilities and providers looking to test patients using real-time RT-polymerase chain reaction (RT-PCR) detection of the SARS-CoV-2 virus (the virus that causes COVID-19) in respiratory specimens. The test uses RT-PCR to detect the virus in upper and lower respiratory specimens.

    Currently, results will be available within 24 hours (one business day) from time of receipt of the sample in the laboratory, with plans to boost testing capacity in the coming week. Precision Genetics’ healthcare technology laboratory has the capability to direct-connect to other laboratories, healthcare systems, and practitioners’ offices to deliver test information within seconds of the results being reported. The laboratory uses a cloud-based information system, Ovation.io, to help expedite the test orders, specimen tracking, and results to support faster response times to the COVID-19 pandemic.

    In addition to COVID-19 testing, Precision Genetics uses an advanced scientific approach to treating employees and patients, using healthcare data to determine the risks associated with medications and complex drug regimens. By combining genetic markers, molecular data, and clinical evidence into a comprehensive and actionable solution, they allow providers to immediately develop individualized treatment and prevention plans for their patients.

    “Healthcare facilities throughout South Carolina were struggling to find COVID-19 test facilities that could provide both accurate and timely results”, said Steve Johnson, SCRA Investment Manager. “Some institutions were waiting eight days or more before receiving results. Other testing services were no longer even accepting any further samples. It was critical that an experienced South Carolina-based lab have the throughput capacity to handle the volume of COVID-19 testing that was predicted to be coming. Because of Precision Genetics’ existing track record of providing excellent advanced molecular testing and innovative solutions to healthcare institutions in the state, SCRA and SC Launch, Inc. are proud to provide this investment to Precision Genetics at a time when their capabilities are critically needed in our state.”

    “This national and statewide pandemic has challenged us as business leaders to create immediate solutions on behalf of our patients and healthcare providers. The challenge in South Carolina is that we lack sufficient laboratory infrastructure to deploy testing solutions in rapid form in order to manage the immenent demand that our state requires. All labs face a similar obstacle of obtaining the necessary resources and supplies to accommodate our patient volumes. SCRA and SC Launch, Inc. stepped up and provided financial commitment and strategic support for us to expedite our efforts. We are desperately trying to serve our community in this time of need, and we are very grateful for the support from SCRA and SC Launch, Inc.” said Nate Wilbourne, CEO of Precision Genetics.

    SCRA is a state-chartered organization that fuels job creation and grows South Carolina’s innovation economy. Through SCRA’s programs, early-stage companies are provided mentoring and grants and may be eligible for an investment from SCRA’s investment affiliate, SC Launch, Inc.

  • Sam Patrick posted an article
    Vikor Scientific plans move to WestEdge in Charleston see more

    Vikor Scientific, a biotech firm that provides targeted diagnostics to improve patient outcomes, is expanding and moving its headquarters into the 22 WestEdge building this spring.

    The building is nearly complete and will include offices for both Vikor Scientific and members of senior management at MUSC Health, according to a news release.

    Vikor, which is currently in offices in Suite 8 at 645 Meeting St. in downtown Charleston, provides medical professionals with diagnostic tools to improve treatments. The company takes a specimen and customizes molecular diagnostic panels to accurately detect and measure pathogens and antibiotic resistance within 12 to 24 hours.

    “At Vikor’s new WestEdge location, together with South Carolina Research Authority, we’re creating a lab and office environment that people in Charleston have been craving for years,” Vikor co-founder Scotty Branch said. “Not only will our workforce feel good about going to work in a state-of-the-art facility looking out over a world-class city, we’re proud to invite scientists from across the country to visit our workspace.”

    There are currently 53 employees at Vikor, and the company is hiring, the release said. The company’s WestEdge headquarters will include executive suites, sales and marketing teams, customer service, supply chain management and payer relations, plus clinicians, neuropharmacologists, medical specialists, researchers and scientists on multiple floors of the building.

    Vikor co-founder and Medical University of South Carolina alumna Shea C. Harrelson said she is aware of potential collaboration opportunities with the neighborhood’s proximity to the medical district.

    “We recently launched our research division, KOR Life Sciences, and we are interested in working with other scientists at MUSC to identify areas where synergy may be possible,” Harrelson said.

    Michael Maher, CEO of The WestEdge Foundation Inc., said Vikor’s presence affirms the WestEdge vision. He said the neighborhood’s current and future living options, restaurants, retail, fitness, gathering and incubator spaces were developed with businesses like Vikor in mind.

    The 22 WestEdge building will be the tallest multitenant office building on the peninsula and in the Charleston metro area when it opens, with 150,000 square feet of office and lab space, plus street-level space for cafes, restaurants and shopping, the release said.

    Upon completion, the entire WestEdge project will encompass more than 3 million square feet of space on 60 acres along the Ashley River.

  • Sam Patrick posted an article
    SCRA Making Huge Contributions to SC business and job growth see more

    New Report Spotlights Heavy-Hitting Contributions to State Business and Job Growth

    In Fiscal Year 2019 (FY19), the South Carolina Research Authority (SCRA) played a major role in boosting jobs and technology-related businesses in South Carolina, with 2.9% technology sector job growth—close to double that of general statewide employment gains—and an impact of $694.38 million on the overall innovation economy. An annual report released this week quantifies metrics and shares the success stories behind these positive statewide trends resulting from the efforts of SCRA and its clients and partners in research, academia, entrepreneurship and industry.  Click here to read the full story, compliments of Midlands Biz.

  • Sam Patrick posted an article
    Nephron's Lou Kennedy appointed by Governbor to SCRA Executive Committee see more

    SCRA, a public, nonprofit corporation chartered to grow South Carolina’s innovation economy and foster job creation, announced the appointment by Gov. Henry McMaster of Lou Kennedy to the SCRA Board of Trustees’ Executive Committee.

    The nine-member group is comprised of the presidents of Clemson University, the Medical University of South Carolina and the University of South Carolina, the governor or designee (to serve as Chairman), an additional appointee of the governor, the chairman of the House Ways and Means Committee or designee, the chairman of the Senate Finance Committee or designee and two additional members.

    Ms. Kennedy is the president, CEO and owner of Nephron Pharmaceuticals Corporation, a woman-owned business that leads the world in the manufacturing of generic respiratory medications. Kennedy received her Bachelor of Arts in Public Relations from the University of South Carolina. She has received numerous awards in South Carolina and across the country for her achievements in business and leadership. Kennedy is also the immediate past chairman of the S.C. Chamber of Commerce and chairman of the Board of Directors of SCBIO, the state's official life sciences organization.

    “I am excited to welcome Ms. Kennedy to SCRA’s Executive Committee,” said Don Herriott, chairman of the SCRA Board. “Her extensive business and leadership experience has had a tremendous positive impact on South Carolina and makes her a valuable addition to the governing body of SCRA.”

  • Sam Patrick posted an article
    South Carolina makes its three-city debut on the Surge Cities list see more

    Today, Greenville, SC debuts on the Surge Cities list at No. 33--one of three South Carolina cities, including Charleston and Columbia, to appear on the list for the first time. Each has drawn on unique strengths to build its startup scene, but all three also benefit from one another's success. Greenville's turnaround began 25 years ago when city leaders began aggressively recruiting manufacturers to tap into the city's underemployed workforce and tax incentives.  Click here to read the full article, compliments of Inc. Magazine.

  • Sam Patrick posted an article
    Biopharma research is an important source of jobs, tax revenue and research spending in SC see more

    New findings show biopharma research companies a source of jobs, tax revenue and research spending in state

     

    GREENVILLE, S.C., October 4, 2018 – This week, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 572 active clinical trials in the South Carolina, and the life science industry supports 29,500 high-quality jobs and contributes $7.9 billion to South Carolina’s economy. These clinical trials can be responsible for more than half of the $2.6 billion average cost of developing one new medicine. They are investigating some of the biggest health care challenges South Carolinians face, including arthritis, cancer, diabetes, cardiovascular disease, and Alzheimer’s disease.

    The report, titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” was released at a press event held at the Westin Poinsett today, which featured a panel discussion including researchers and executives from the Greenville Health System, KIYATEC, the Hollings Cancer Center at MUSC, and the Greenwood Genetic Center, moderated by SCBIO President and CEO, Sam Konduros.

    “Clinical trials offer patients novel medical treatments right here in the Palmetto State, while also allowing biopharma research organizations to innovate and grow,” said Konduros. “Across South Carolina, the life sciences and healthcare industries have had a profound impact on our economy and citizens, that continues to rapidly increase.”

    Clinical trials are a vital component of bringing new life-saving drugs and treatments to market. On average, it takes approximately a decade for new medicines to go through the rigorous Food and Drug Administration (FDA) approval process. Only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted or are currently conducting more than 4,700 clinical trials in South Carolina. In 2013 alone, the nearly 1,100 active clinical trials in the state generated an estimated economic impact of $540 million.

    “One of the most important things we want people to understand about medicine development is that clinical trials rely on patient participation,” said Nick McGee, Director of Public Affairs for PhRMA. “It’s incredibly important that patients are aware of ongoing trials and learn how they can help become part of finding a cure for the toughest chronic conditions and diseases we face today.”

    In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations combined. In South Carolina, of the 572 open clinical trials involving the biopharmaceutical research industry, the University of South Carolina Medial School is collaborating on more than 143 clinical trials and the Medical University of South Carolina is collaborating on more than 142.

    “Many top research and medical universities call South Carolina home and are centers of innovation,” Bob Quinn, Executive Director of the South Carolina Research Authority, said. “Maintaining strong partnerships between our universities and life science companies allows us to foster developments right here in South Carolina that can then help save lives far beyond our state lines.”

    You can read the complete report, “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” here.

    ###

    About PhRMA
    The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $71.4 billion in 2017 alone.

    About SC BIO
    SCBIO is South Carolina’s investor-driven public/private economic development organization focused on building, advancing, and growing the life sciences industry in the state.  With an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products that make a difference across the Palmetto State and around the world.  Visit us at SCBIO.org.

  • Sam Patrick posted an article
    South Carolina's Zylö Therapeutics Closes $4 Million Financing round see more

    GREENVILLE, SC: September 26, 2019: Zylö Therapeutics Inc., dedicated to developing a transformational topical delivery platform, announced that on September 21, 2019, it effected a closing of its Series A financing through the sale of $4 million of Series A preferred shares. Approximately $1.35 million of this total was invested prior to this year and was converted into Series A shares as part of this financing.

    The remaining $2.65 million was newly invested capital, led by VentureSouth with investments totaling more than $1 million. VentureSouth, one of the largest early-stage investment groups in the country, has more than 300 private investors in 12 local chapters across the Southeast and has invested nearly $40 million in 67 companies. Other angel groups investing in this round include the New York Angels, Ariel Southeast Angel Partners (ASAP) out of Savannah, the Boston Harbor Angels, and the Chemical Angel Network.

    SC Launch Inc., an affiliate of the South Carolina Resource Authority (SCRA)—a non-profit corporation chartered by the state that helps fuel South Carolina’s innovation economy—also participated in this round.

    In addition, insiders and their affiliates/associates invested over $400,000, extending their total invested to over $1.5 million.

    Proceeds from the funding will be used to further scale up the manufacturing process of the company’s Z-pod™ delivery particles and for general working-capital and business-development purposes, as Zylö aims to forge 21 partnerships by 2021.

    “This funding enables us to secure additional partnerships similar to the one recently announced by HOTH Therapeutics, a biopharmaceutical company that has licensed from Zylö endocannabinoid-releasing Z-pods™ to treat lupus,” stated Scott Pancoast, Zylö CEO and Founder. “The additional capital also allows us to move ahead with a number of other initiatives such as the Lidocaine Patchless Patch™ as both an Rx and an Over-The-Counter drug product; a sustained-release topical CBD product, which has blockbuster potential; and a sustained-release nitric oxide cream for anti-aging, wound-healing, acne, nail fungus, and other applications.”

    He continued, “We appreciate the confidence expressed by our new and existing investors in the potential of our underlying Z-pod™ technology and our leading product candidates.”

    About Zylö Therapeutics:
    Zylö has developed an innovative topical delivery system that extends the duration-of-effect, improves the solubility/targeting, and/or enhances the product performance of many therapeutic agents. Notably, the Z-pod™ technology platform has enabled the Patchless Patch™ concept and has successfully harnessed the therapeutic potential of nitric oxide, one of the most powerful—and short-lived—biomolecules produced by our bodies. For more details please visit our web site, www.zylotherapeutics.com and follow us on Twitter (@ZyloTherapies).

  • Sam Patrick posted an article
    SCRA Celebrates $1 Billion in Support of South Carolina Start-Ups see more

    Summerville, S.C.– SCRA, a public, non-profit corporation that fuels South Carolina’s innovation economy, celebrated a milestone of $1 billion of follow-on capital secured by Client Companies in the SC Launch Program. SC Launch, SCRA’s entrepreneurial program, provides mentoring, grants and access to SC Launch, Inc. investments for qualified, South Carolina-based, early-stage companies.

    Access to follow-on capital is critical to the success of entrepreneurial companies. Angel investors, venture capital funds and corporate investors are the main source of follow-on funding secured by SC Launch companies. The $1 billion in follow-on investments were acquired by more than 140 Client Companies over the span of 12 years.

    “Our job, and our passion, is guiding companies to the next stage in the entrepreneurial life cycle and seeing them through to success,” said Bob Quinn, SCRA Executive Director, “The funding provided by SC Launch is vital in enabling our Client Companies to overcome many of the barriers faced by early-stage enterprises. However, void of follow-on funding, these companies often flounder. Therefore, we are thrilled to be celebrating this $1 billion milestone.”

    “Through the SC Launch Program, SCRA helps entrepreneurs to strategically navigate the ups and downs of running a company. We also work alongside entrepreneurs to secure grants, prepare them for investments and secure capital from other sources.” said Jill Sorensen, SCRA Director of Entrepreneurial Programs and Executive Director of SC Launch, Inc. “Our team rolls up our sleeves and dives in to provide an advantage for the entrepreneurs we support.”

    SCRA is a state-chartered organization that fuels job creation and grows South Carolina’s innovation economy. The SC Launch Program is open to qualified South Carolina companies in the Advanced Materials/Manufacturing, Information Technology and Life Sciences sectors.

    ###

    About SCRA
    Chartered in 1983 by the State of South Carolina as a public, non-profit corporation, SCRA fuels South Carolina’s Innovation Economy by supporting entrepreneurs, enabling academic research and its commercialization, and connecting industry to innovators.

  • Sam Patrick posted an article
    USEDA awards major grant to South Carolina group see more

    Summerville, S.C.– SCRA has been awarded approximately $750,000 in federal grant funding by the U.S. Economic Development Administration (EDA) as part of the 2018 Regional Innovation Strategies Competition. The grant will fund the creation of the South Carolina Medical Device Alliance to invent and develop products and bring them to market. This partnership, comprised of Clemson University, the Medical University of South Carolina and industry leaders, will form a regional innovation cluster to grow the economic impact of the medical device industry through job creation and startup formation, as well as to attract international businesses to establish a presence in South Carolina. The project total is $1,814,846, which includes the federal grant funding and matching funds.

    “We are honored to be one of forty recipients nationwide,” said Christine Dixon Thiesing, SCRA’s Director of Academic Programs. “This program will serve South Carolina’s academic institutions and clinical innovators to overcome challenges inherent in the commercialization of medical devices. Building the medical device sector will also diversify South Carolina’s economy strategically by leveraging the existing skilled workforce and fostering a broader range of job opportunities for its workers.”

    “MUSC’s Foundation for Research Development (FRD) is excited to be partnering with SCRA on this project,” said Michael Rusnak, Executive Director of FRD. “This gives MUSC one more vehicle to advance medical device technologies through our company startup activities; a substantial win for local economic development and more importantly, patients.”

    “I am constantly amazed by the creativeness and vision that our students bring to their senior design projects here at Clemson,” said Dr. John DesJardins, Director of Clemson Bioengineering’s Undergraduate Design Program. “Our clinical and industry partnerships in design are essential to this educational process, and we are excited to have the medical devices invented in our senior design program serve as a pipeline in the development and commercialization of innovative biomedical devices.”

    The Office of Innovation and Entrepreneurship, housed within the U.S. Department of Commerce’s Economic Development Administration, leads the Regional Innovation Strategies Program to spur innovation capacity-building activities in regions across the nation.

    To learn more about the South Carolina Medical Device Alliance, including the scope of work and key personnel click here.

    SCRA is a state-chartered organization that fuels South Carolina’s innovation economy by accelerating technology-enabled growth in research, academia, entrepreneurship and industry.

  • Sam Patrick posted an article
    Grant to fund creation of the South Carolina Medical Device Alliance to invent and develop products see more

    SCRA has been awarded approximately $750,000 in federal grant funding by the U.S. Economic Development Administration (EDA) as part of the 2018 Regional Innovation Strategies Competition. The grant will fund the creation of the South Carolina Medical Device Alliance to invent and develop products and bring them to market. This partnership, comprised of Clemson University, the Medical University of South Carolina and industry leaders, will form a regional innovation cluster to grow the economic impact of the medical device industry through job creation and startup formation, as well as to attract international businesses to establish a presence in South Carolina. The project total is $1,814,846, which includes the federal grant funding and matching funds.

    “We are honored to be one of forty recipients nationwide,” said Christine Dixon Thiesing, SCRA’s Director of Academic Programs. “This program will serve South Carolina’s academic institutions and clinical innovators to overcome challenges inherent in the commercialization of medical devices. Building the medical device sector will also diversify South Carolina’s economy strategically by leveraging the existing skilled workforce and fostering a broader range of job opportunities for its workers.”

    The Office of Innovation and Entrepreneurship, housed within the U.S. Department of Commerce’s Economic Development Administration, leads the Regional Innovation Strategies Program to spur innovation capacity-building activities in regions across the nation.

    “MUSC’s Foundation for Research Development (FRD) is excited to be partnering with SCRA on this project,” said Michael Rusnak, Executive Director of FRD. “This gives MUSC one more vehicle to advance medical device technologies through our company startup activities; a substantial win for local economic development and more importantly, patients.”

    To learn more about the South Carolina Medical Device Alliance, including the scope of work and key personnel click here.

    SCRA is a state-chartered organization that fuels South Carolina’s innovation economy by accelerating technology-enabled growth in research, academia, entrepreneurship and industry.

  • Sam Patrick posted an article
    NEW LIFE SCIENCES DISTRICT KICKS OFF CONSTRUCTION IN CHARLESTON, SC AT WESTEDGE see more

    Charleston, SC - July 17, 2018 marked the construction kickoff for 22 WestEdge, a striking new workplace anchor for the city’s growing knowledge economy and the highly anticipated centerpiece of the WestEdge District. The iconic 125-foot, eight-story structure will be the tallest multi-tenant office building on the peninsula and in Charleston’s metropolitan area when it opens in November 2019.

    “22 WestEdge affirms the vision for a Live, Learn and Earn district, adding vital office, research and lab components to the world class WestEdge community. It builds on the remarkable momentum of a development that already has over $300 million under construction,” said Michael Maher, CEO of The WestEdge Foundation, Inc., the non-profit sponsor of the overall development.

    Even prior to the 22 WestEdge groundbreaking, area economic development proponents including The Medical University of South Carolina, the South Carolina Research Authority, the City of Charleston, Heritage Trust and the WestEdge Foundation committed to 22 WestEdge, forming the nucleus of entities working to incubate, attract and retain entrepreneurial talent to energize the Charleston economy.  While 48% of the space is currently leased, 72,000 square feet of office space and 10,000 square feet of retail space remain available for existing local businesses, or for new companies being created or relocating to the Charleston region. This is a remarkable concentration of ingenuity¾over 35,000 people live, work, study and seek healthcare expertise in the adjacent medical district.

    Partnership and innovation opportunities abound for 22 WestEdge tenants—with unprecedented access to like-minded neighbors and colleagues in Charleston’s life sciences sector. Dr. David Cole, President of MUSC shared, “With MUSC’s $275 million of research and proprietary discoveries, 22 WestEdge will allow the University to collaborate with private industry to create new healthcare solutions, new companies and recruit existing global medical-related companies to Charleston.” Bob Quinn, Executive Director of the SCRA agreed, “SCRA’s leasing of the entire top floor of 22 WestEdge will allow us to create a world-class facility, including laboratories, which will serve as a catalyst for the attraction of leading life sciences companies and the creation of a Discovery District adjacent to MUSC.”  

    Charleston Mayor John Tecklenburg echoed, “It’s no secret that biomedical advances will be a key driver of our economy and society in the years ahead. With 156,000 square feet of office space dedicated to precisely the kind of research and enterprise that will help make those breakthroughs possible, 22 WestEdge is a welcome and important addition to our city’s medical district.”

    22 WestEdge office tenants will also benefit from the energy and vitality of the district. Recently completed, The Caroline has 237 apartments and 20,000 square feet of retail and restaurant space, and the topped-out 10 WestEdge will have 350 residential units, a Publix Super Market, Woodhouse Spa and additional retail and restaurant space, providing an abundance of shopping, eating and living options for all. 22 WestEdge’s own amenities include 15,000 square feet of cafes and fitness facilities, common conference and event facilities and a terrace wrapping the 7th floor with sweeping views of the Ashley River. Mack Reese, 22 WestEdge developer and partner, explains his reason for developing the project, “With its access to parking, numerous retail amenities and an urban density of residential opportunities for employees, the building will be a new and exciting option for existing Charleston businesses and those looking to relocate to the region.”

    Upon completion, WestEdge’s master-planned mixed-use district will encompass more than 3,000,000 square feet of space on 60 acres along the Ashley River adjacent to MUSC and the Medical District, and fronting on Brittlebank Park and the Joseph Riley Baseball Stadium. WestEdge is a public-private partnership created to advance economic development and expand the research capabilities of the Medical University of South Carolina and foster new companies and collaborative opportunities with private industry. It is an innovative redevelopment that is transforming the quality of life for Charleston’s west side.

    Key 22 WestEdge partners include Gateway Development (Developer) ELV Associates (Investor), BB&T (Lender), Trident Construction (General Contractor), Perkins & Will (Architect), Thomas and Hutton (Civil Engineer), and Lee & Associates (Marketing & Leasing).  

    For leasing inquiries and further detail on WestEdge development, please contact Mack Reese of Gateway Development (770-310-3414 ).  

  • Sam Patrick posted an article
    South Carolina's life sciences industry is booming. Read on for details... see more

    From pharmaceuticals and medical devices to research and laboratory testing, the state's life sciences field is booming.  The Charleston and Lowcountry region is home to many established companies and start-ups making a mark on the biomedical and health industries.  Read on for the full story from Charleston Business Magazine's 2018 State of the Lowcountry Report.